10-K.Info (Beta Test)
Courtesy of Short Sands, LLC
Income Statement Comp. Income Cash Flow Balance Sheet All Statements
2009 2010 2011 2012 2013 2014 2015
2016 2017 2018 2019 2020 2021 2022
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2014

CONSOLIDATED STATEMENTS OF EARNINGS

Period Ending Dec 31, 2014 10-K (Filed: Feb 13, 2015)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2014Dec 31, 2013Dec 31, 2012
Net product sales
$
11,660
12,30413,654
Alliance and other revenues4,2194,0813,967
Total Revenues15,87916,38517,621
Cost of products sold3,9324,6194,610
Marketing, selling and administrative4,0884,0844,220
Advertising and product promotion734855797
Research and development4,5343,7313,904
Impairment charge for BMS-986094 intangible asset1,830
Other (income)/expense210205(80)
Total Expenses13,49813,49415,281
 
Earnings Before Income Taxes2,3812,8912,340
 
Provision for/(Benefit from) Income Taxes352311(161)
Net Earnings2,0292,5802,501
 
Net Earnings Attributable to Noncontrolling Interest2517541
Net Earnings Attributable to BMS2,0042,5631,960
 
Earnings per Common Share
Basic Earnings Per Common Share Attributable to BMS1.211.561.17
Diluted Earnings per Common Share Attributable to BMS1.201.541.16
Cash dividends declared per common share1.451.411.37
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2014

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Period Ending Dec 31, 2014 10-K (Filed: Feb 13, 2015)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2014Dec 31, 2013Dec 31, 2012
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]
Net Earnings
$
2,029
2,5802,501
Other Comprehensive Income (Loss), net of taxes and reclassifications to earnings [Abstract]
Derivatives qualifying as cash flow hedges697(27)
Pension and postretirement benefits(324)1,166(118)
Available-for-sale securities3(37)3
Foreign currency translation(32)(75)(15)
Total Other Comprehensive Income/(Loss)(284)1,061(157)
 
Comprehensive Income1,7453,6412,344
 
Comprehensive Income Attributable to Noncontrolling Interest2517535
Comprehensive Income Attributable to BMS1,7203,6241,809
 
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2014

CONSOLIDATED STATEMENTS OF CASH FLOWS

Period Ending Dec 31, 2014 10-K (Filed: Feb 13, 2015)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2014Dec 31, 2013Dec 31, 2012
Cash Flows From Operating Activities:
Net Earnings
$
2,029
2,5802,501
Adjustments to reconcile net earnings to net cash provided by operating activities:
Net earnings attributable to noncontrolling interest(25)(17)(541)
Depreciation and amortization, net467763681
Deferred income taxes(542)(491)(1,230)
Stock-based compensation213191154
Impairment charges401402,180
Pension settlements and amortization971294292
Proceeds from Amylin diabetes alliance3,570
Gain on sale of businesses and other(567)(9)(35)
Changes in operating assets and liabilities:
Receivables(252)(504)648
Inventories(254)(45)(103)
Accounts payable(44)412(232)
Deferred income613965295
Income taxes payable171126(50)
Other(33)(760)(1,189)
Net Cash Provided by Operating Activities3,1483,5456,941
 
Cash Flows From Investing Activities:
Proceeds from sale and maturities of marketable securities4,0951,8154,890
Purchases of marketable securities(5,719)(1,859)(3,607)
Additions to property, plant and equipment and capitalized software(526)(537)(548)
Business divestitures and other proceeds3,585968
Business acquisitions and other payments(219)(7,530)
Net Cash Provided by/(Used in) Investing Activities1,216(572)(6,727)
 
Cash Flows From Financing Activities:
Short-term debt borrowings, net24419849
Proceeds from issuance of long-term debt1,4891,950
Repayments of long-term debt(676)(597)(2,108)
Interest rate swap contract terminations105202
Issuances of common stock288564463
Repurchases of common stock(433)(2,403)
Dividends(2,398)(2,309)(2,286)
Net Cash Used in Financing Activities(2,437)(1,068)(4,333)
 
Effect of Exchange Rates on Cash and Cash Equivalents5825(1)
Increase/(Decrease) in Cash and Cash Equivalents1,9851,930(4,120)
 
Cash and Cash Equivalents at Beginning of Year3,5861,656
Cash and Cash Equivalents at End of Year5,5713,5861,656
 
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2014

CONSOLIDATED BALANCE SHEETS

Period Ending Dec 31, 2014 10-K (Filed: Feb 13, 2015)

(In Millions, except shares in actual)
 As ofAs of
 Dec 31, 2014Dec 31, 2013
ASSETS
Current Assets:
Cash and cash equivalents
$
5,571
3,586
Marketable securities, current1,864939
Receivables3,3903,360
Inventories1,5601,498
Deferred income taxes, current1,6441,701
Prepaid expenses and other470412
Assets held-for-sale1097,420
Total Current Assets14,60818,916
 
Property, plant and equipment4,4174,579
Goodwill7,0277,096
Other intangible assets1,7532,318
Deferred income taxes915508
Marketable securities, noncurrent4,4083,747
Other assets6211,428
Total Assets33,74938,592
 
LIABILITIES
Current Liabilities:
Short-term borrowings590359
Accounts payable2,4872,559
Accrued expenses2,4592,152
Deferred income, current1,167756
Accrued rebates and returns851889
Income taxes payable, current262160
Dividends payable645634
Liabilities related to assets held-for-sale4,931
Total Current Liabilities8,46112,440
 
Pension, postretirement, and postemployment liabilities1,115718
Deferred income, noncurrent770769
Income taxes payable, noncurrent560823
Other liabilities618625
Long-term debt7,2427,981
Total Liabilities18,76623,356
 
Commitments and contingencies (Note 22)  
EQUITY
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,212 in 2014 and 4,369 in 2013, liquidation value of $50 per share00
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2014 and 2013221221
Capital in excess of par value of stock1,5071,922
Accumulated other comprehensive loss(2,425)(2,141)
Retained earnings32,54132,952
Less cost of treasury stock - 547 million common shares in 2014 and 559 million in 2013(16,992)(17,800)
Total Bristol-Myers Squibb Company Shareholders' Equity14,85215,154
 
Noncontrolling interest13182
Total Equity14,98315,236
 
Total Liabilities and Equity33,74938,592
 
External Links 
BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2014
Statements of 10-K in Excel https://www.sec.gov/.../Financial.xlxs
Complete 10-K in HTML https://www.sec.gov/.../10-K.html
Complete 10-K in XBRL https://www.sec.gov/.../10-K-xbrl.zip